Aurora BayCare Medical Center, Green Bay, USA.
J Oncol Pharm Pract. 2021 Oct;27(7):1795-1798. doi: 10.1177/10781552211002629. Epub 2021 Mar 18.
Pemigatinib is an FGFR inhibitor that is one of few second-line treatment options for cholangiocarcinoma. Nail toxicities were common in the phase 2 study evaluating the safety and efficacy of pemigatinib.
We describe a 54-year-old female with a history of stage IV cholangiocarcinoma presenting for a follow-up visit after completing Cycle 4 of pemigatinib. The patient had been having significant nail changes to her fingernails and toenails, which has led to her great toenails falling off. The patient was prescribed betamethasone dipropionate 0.05% cream to help with her nail changes and instructed to continue vinegar and hot water soaks that she had already been doing. It was discussed that if this did not help with her nail changes, treatment may have to be held for 2 weeks to allow her nails to heal.
Nail changes are a common side effect with pemigatinib and should be monitored closely for the need for temporary disruption in therapy.
培米替尼是一种 FGFR 抑制剂，是胆管癌二线治疗方案之一。在评估培米替尼安全性和疗效的 2 期研究中，指甲毒性很常见。
我们描述了一位 54 岁女性，患有 IV 期胆管癌，在完成培米替尼第 4 周期后进行随访。该患者的手指甲和脚趾甲发生了严重的变化，导致大脚趾甲脱落。给患者开了倍他米松二丙酸酯 0.05%乳膏来治疗指甲变化，并指示她继续使用她已经在使用的醋和热水浸泡。医生还讨论了如果这种治疗方法对指甲变化没有帮助，可能需要暂停治疗 2 周，让指甲愈合。
指甲变化是培米替尼的常见副作用，应密切监测是否需要暂时中断治疗。
